All In Biotech

Drug Trial Radar · NCT07326566

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

162

Planned (sponsor's estimate)

Start

May 5, 2026

Primary completion

Nov 2028

Study completion Mar 2029

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?

Conditions

  • Glioblastoma (GBM)
  • Newly Diagnosed Glioblastoma
  • GBM
  • Glioblastoma Multiforme (GBM)
  • Glioma
  • Central Nervous System Diseases
  • Brain Cancer

Interventions

  • silevertinib in combination with temozolomideDrug

    Participants enrolled into Part 1 (Safety Lead-In) or randomized to Arm A in Part 2 will receive silevertinib at dose determined in Part 1 until disease progression in combination with temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles.

  • temozolomide (TMZ)Drug

    Participants randomized to Arm B will receive temozolomide 150-200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle for maximum of 6 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)Time frame: 12 months

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

    Birmingham, Alabama · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • UCSD Moores Cancer Center

    La Jolla, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UC Irvine Health

    Orange, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Johns Hopkins Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Piedmont Oncology Research

    Atlanta, Georgia · Recruiting

  • Maine Health Cancer Care and Blood Disorders - Scarborough

    Scarborough, Maine · Recruiting

  • Johns Hopkins Sidney Kimmel Cancer Center - Baltimore

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer- Detroit

    Detroit, Michigan · Recruiting

  • Atrium Health Levine Cancer Institute

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Atlantic Health

    Summit, New Jersey · Recruiting

  • Northwell Health Center for Advanced Medicine - Brain Tumor Center

    Lake Success, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Prisma Health

    Greenville, South Carolina · Recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia · Recruiting

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.